Unraveling Potential Sex‐Specific Effects of Cardiovascular Medications on Longevity Using Mendelian Randomization

Author:

Kwok Man Ki12ORCID,Schooling C. Mary23ORCID

Affiliation:

1. School of Nursing and Health Studies, Hong Kong Metropolitan University Hong Kong China

2. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong Hong Kong China

3. City University of New York Graduate School of Public Health and Health Policy New York NY

Abstract

Background Establishing the sex‐specific efficacy of cardiovascular medications is pivotal to evidence‐based clinical practice, potentially closing the gender gap in longevity. Trials large enough to establish sex differences are unavailable. This study evaluated sex‐specific effects of commonly prescribed cardiovascular medications on lifespan. Methods and Results In a two‐sample Mendelian randomization study, established genetic variants mimicking effects of lipid‐lowering drugs, antihypertensives, and diabetes drugs were applied to genetic associations with lifespan proxied by UK Biobank maternal (n=412 937) and paternal (n=415 311) attained age. Estimates were obtained using inverse variance weighting, with sensitivity analyses where possible. For lipid‐lowering drugs, genetically mimicked PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors were associated with longer lifespan, particularly in men (2.39 years per SD low‐density lipoprotein cholesterol reduction [95% CI, 0.42–4.36],  P for interaction=0.14). Genetically mimicked treatments targeting APOC3 , LPL , or possibly LDLR were associated with longer lifespan in both sexes. For antihypertensives, genetically mimicked β‐blockers and calcium channel blockers were associated with longer lifespan, particularly in men ( P for interaction=0.17 for β‐blockers and 0.31 for calcium channel blockers). For diabetes drugs, genetically mimicked metformin was associated with longer lifespan in both sexes. No associations were found for genetically mimicked statins, ezetimibe, or angiotensin‐converting enzyme inhibitors. Conclusions PCSK9 inhibitors, β‐blockers, and calcium channel blockers may prolong lifespan in the general population, particularly men. Treatments targeting APOC3 , LPL , or LDLR and metformin may be relevant to both sexes. Whether other null findings are attributable to lack of efficacy requires investigation. Further investigation of repurposing should be conducted.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference66 articles.

1. United Nations Economic Commission for Europe (UNECE) . Gender equality in ageing societies ‐ UNECE Policy Brief on Ageing No. 23. 2020. Accessed 01 Jan 2022. https://unece.org/fileadmin/DAM/pau/age/Policy_briefs/ECE_WG‐1_34.pdf

2. WHO report shows that women outlive men worldwide

3. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

4. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

5. NIH Inclusion Policies. NIH Office of Research on Women's Health. 2020. Accessed August 18 2020. https://orwh.od.nih.gov/womens‐health/clinical‐research‐trials/nih‐inclusion‐policies

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3